Good morning, everyone, and how are you today? We are doing just fine, thank you, especially now that the middle of the week has arrived. Why? Well, this means there is not much more time until the end of the week arrives. You know, we try to see the glass as half full (instead of just being a glass). So on that optimistic note, please join us for a delicious cup of stimulation. Our choice today is the seasonal pumpkin spice. Feel free to join us. Meanwhile, here are a few items of interest to help you along. Have a great day, stay safe — and wear a mask. …

A federal government-sponsored clinical trial that is testing an antibody treatment for Covid-19 developed by Eli Lilly (LLY) has been paused because of a “potential safety concern,” STAT writes. However, the National Institutes of Health did not indicate whether it was the treatment group or the placebo group that may have crossed a safety threshold. The trial was designed to test the benefits of the drug on hundreds of hospitalized Covid-19 patients, compared with a placebo.

Unlock this article by subscribing to STAT Plus and enjoy your first 30 days free!

GET STARTED

What is it?

STAT Plus is STAT's premium subscription service for in-depth biotech, pharma, policy, and life science coverage and analysis. Our award-winning team covers news on Wall Street, policy developments in Washington, early science breakthroughs and clinical trial results, and health care disruption in Silicon Valley and beyond.

What's included?

  • Daily reporting and analysis
  • The most comprehensive industry coverage from a powerhouse team of reporters
  • Subscriber-only newsletters
  • Daily newsletters to brief you on the most important industry news of the day
  • STAT+ Conversations
  • Weekly opportunities to engage with our reporters and leading industry experts in live video conversations
  • Exclusive industry events
  • Premium access to subscriber-only networking events around the country
  • The best reporters in the industry
  • The most trusted and well-connected newsroom in the health care industry
  • And much more
  • Exclusive interviews with industry leaders, profiles, and premium tools, like our CRISPR Trackr.
Sign up to receive a free weekly opinions recap from our community of experts.
Privacy Policy